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Abstract
Spinal Muscular Atrophy (SMA), a recessive hereditary neurodegenerative disease in humans, has been linked to mutations
in the survival motor neuron (SMN) gene. SMA patients display early onset lethality coupled with motor neuron loss and
skeletal muscle atrophy. We used Drosophila, which encodes a single SMN ortholog, survival motor neuron (Smn), to model
SMA, since reduction of Smn function leads to defects that mimic the SMA pathology in humans. Here we show that a
normal neuromuscular junction (NMJ) structure depends on SMN expression and that SMN concentrates in the post-
synaptic NMJ regions. We conducted a screen for genetic modifiers of an Smn phenotype using the Exelixis collection of
transposon-induced mutations, which affects approximately 50% of the Drosophila genome. This screen resulted in the
recovery of 27 modifiers, thereby expanding the genetic circuitry of Smn to include several genes not previously known to
be associated with this locus. Among the identified modifiers was wishful thinking (wit), a type II BMP receptor, which was
shown to alter the Smn NMJ phenotype. Further characterization of two additional members of the BMP signaling pathway,
Mothers against dpp (Mad) and Daughters against dpp (Dad), also modify the Smn NMJ phenotype. The NMJ defects caused
by loss of Smn function can be ameliorated by increasing BMP signals, suggesting that increased BMP activity in SMA
patients may help to alleviate symptoms of the disease. These results confirm that our genetic approach is likely to identify
bona fide modulators of SMN activity, especially regarding its role at the neuromuscular junction, and as a consequence,
may identify putative SMA therapeutic targets.
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Introduction
Spinal Muscular Atrophy (SMA) is the second most common
autosomal recessive genetic disease in humans and is the leading
cause of genetically linked infant mortality, with an incidence rate
of approximately 1 in 6000 births [1,2,3]. Clinical manifestation of
SMA shows degeneration of spinal cord motor neurons and
muscle atrophy [4]. SMA has also been linked to two nearly
identical genes located on chromosome 5, survival motor neuron 1
(SMN1) and survival motor neuron 2 (SMN2) [5]. SMN2 differs from
SMN1 in that only 10% of SMN2 transcripts produce functional
Smn protein (SMN) due to a mutation that results in its aberrant
splicing [6,7,8].
Elegant biochemical studies established the importance of the
SMN protein in a ubiquitous, multimeric complex involved in the
assembly of spliceosomal small nuclear ribonucleoproteins
(snRNPs) [9,10,11,12,13,14]. Despite its seemingly fundamental
and indispensable role in cellular metabolism, reduction of SMN
leads to a specific neurodegenerative profile associated with this
disease [1,15,16,17,18]. Though several recent studies indicate
that SMN influences motor neuron axonal morphology [19,20], it
remains unclear whether SMN has a specific neuromuscular
junction (NMJ) function, and whether the functional requirement
for SMN activity is increased at the NMJ than elsewhere in the
organism.
SMA results from loss of SMN1 function [6,21], however, the
clinical severity of the disease correlates with SMN2 copy number,
which varies between individuals [22]. As the small amount of
functional SMN2 protein produced by each copy is capable of
partially compensating for the loss of the SMN1 gene function,
higher copy numbers of SMN2 result in generally milder forms of
SMA. Given that the severity of SMA depends on the levels of
functional SMN, genetic modifiers capable of altering SMN
cellular activity may define useful therapeutic targets. This
reasoning prompted us to explore the genetic circuitry capable
of affecting SMN activity in Drosophila, an experimental model
amenable to sophisticated genetic manipulations, to investigate the
role of SMN in this system.
The Drosophila genome harbors a single copy of the Smn gene,
which encodes a highly conserved homologue of SMN. The Smn
loss of function allele, Smn
73Ao, results in recessive larval lethality
and, importantly, neuromuscular junction abnormalities
[15,18,23]. In this study, we characterized additional Smn alleles
and demonstrate that they also display NMJ defects. To analyze
tissue-specific requirements of SMN, we used RNA interference
(RNAi) to create a series of loss of function Smn alleles, whose
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pathology. By using muscle (mesoderm) and neuronal drivers to
direct expression of the Smn RNAi constructs, we determined that
SMN function is required in both tissues, though there appears to
be a higher sensitivity to the loss of SMN function in the muscle.
To identify enhancers and suppressors of SMN activity and the
genetic circuitry of Smn, we carried out a genetic screen for
modifiers of the Smn
73Ao allele using the Exelixis collection of
insertional mutations, which affects approximately 50% of the
Drosophila genome [24,25,26]. Of the 17 enhancers and 10
suppressors uncovered by the screen, a significant subset was
shown to be capable of affecting Smn-related NMJ phenotypes,
validating our approach. Amongst these Smn modifiers was wishful
thinking (wit), which encodes a type II BMP receptor [27,28].
Further experiments defined genetic interactions between Smn and
other members of the BMP signaling pathway. We also
demonstrated that modulation of BMP signaling rescues Smn-
related NMJ phenotypes, further validating this genetic approach
as a means to identify novel targets of SMN function. Moreover, it
seems likely that some of the novel targets may provide potential
therapeutic value.
Results
SMN concentrates in the post-synaptic regions at the
NMJ
The dichotomy between the ubiquitous housekeeping function
of Smn and the very specific neuromuscular SMA phenotype raises
the question whether Smn functions differently at the neuromus-
cular junction (NMJ) than in other tissue types. Specifically,
whether SMN has a differential expression pattern in neurons and
muscle and whether SMN concentrates to any particular cellular
compartments at the NMJ remain open questions.
To determine in which tissue(s) SMN is expressed in Drosophila
we raised antibodies against full-length Drosophila SMN (See
Materials and Methods) and monitored its expression pattern
particularly at the NMJ. In Western blots performed on lysates
derived from S2 cells, 3
rd instar larvae and wild-type adult heads
the antibody recognizes a single ,28 kD band [18], correspond-
ing to the predicted molecular weight of Drosophila SMN (Figure S1
and data not shown). Moreover, when a FLAG-tagged Smn
transgenic construct (UAS-FLAG-Smn) was expressed under the
control of the vestigialGAL4 driver, SMN and FLAG staining
overlapped at the dorsal-ventral (DV) boundary of 3
rd instar larval
wing discs. In addition, vestigialGAL4-directed expression of an
inducible RNAi allele of Smn (see below) abolished the SMN
staining pattern along the DV boundary of the larval wing disc
(Figure S1). Together, these results indicate the specificity of the
antibody we raised against SMN.
Using this antibody we probed SMN expression at the NMJ and
found antigens to be clearly concentrated at the post-synaptic
regions in the muscle, co-localizing with the post-synaptic marker
Discs Large (DLG) (Figure 1A–D) [29]. Under these conditions,
we did not detect antigens in the pre-synaptic region of the motor
neuron terminal (as defined by horseradish peroxidase (HRP)
staining) at the NMJ (Figure 1A–D). SMN staining was also
observed within muscle fibers and at discrete foci in muscle nuclei
(Figure 1C and E), which presumably reflect SMN localization in
Cajal bodies (gems) as demonstrated for mammalian cells [9], and
in Drosophila ovarian nurse cells and oocytes [30]. This post-
synaptic NMJ expression pattern of SMN is abolished by muscle-
specific Smn RNAi knockdown, again demonstrating the specificity
of the anti-SMN antibodies (Figure S2). Consistent with its general
role in snRNP assembly, SMN was detected in all tissues
examined, including muscle (Figure 1A–D) and neurons
(Figure 1F). However, at the Drosophila NMJ, SMN is concentrated
at the post-synaptic regions in the muscle.
Mutations in Smn compromise viability
Previous studies determined that loss of Smn function results in
larval lethality [15,18]. We examined two additional Smn alleles
found within the Exelixis collection, Smn
f01109 and Smn
f05960
[25,26]. Sequence analysis of both strains indicates each allele
harbors a transposon insertion within the Smn coding region (at
amino acids I93 for Smn
f01109 and K136 for Smn
f05960, see
Figure 2A) that is predicted to introduce a premature stop codon.
(Figure 2A). Unlike the Smn
73Ao allele [15,18], which is 100%
lethal in homo- and hemizygous (Smn
73Ao/Df(Smn)) backgrounds
(Figure 2B), the Smn
f05960 allele produces a small percentage of
escapers (3.3%) when mutant larvae are isolated and cultured at
low density. On the other hand, Smn
f01109 allele is semi-viable
(67.7%) (Figure 2B), indicating that the Smn
f01109 and Smn
f05960
alleles are not null mutations as previously suggested [18]. By
examining the viability of various Smn allelic combinations
(Figure 2B), we determined that Smn
f01109 is weakly hypomorphic
as it retains some degree of viability in all cases tested, while
Smn
f05960 appears to act as a strong loss-of-function allele since it
fails to complement both Smn
73Ao and a small deficiency that
uncovers Smn, Df(3L)Smn
X7 (Figure 2B). Ubiquitous (tubulinGAL4,
actinGAL4) expression of UAS-FLAG-Smn rescued Smn
f05960 lethal-
ity, demonstrating the lethality was associated with a loss of Smn
activity. This is consistent with earlier studies showing ectopic
SMN expressed under the control of a ubiquitous driver
(tubulinGAL4) rescued Smn
73Ao lethality [15].
Constructing RNAi-based hypomorphic Smn alleles
Since the clinical severity of SMA correlates with the amount of
SMN expression, we sought to better model the disease by
generating a set of Smn alleles with varying degrees of SMN
activity using RNAi. A GAL4-inducible vector was used to
produce three different double-stranded RNAi transgenic con-
structs targeted against the full-length SMN protein (FL) as well as
the amino-terminal (N) (the entire 59 portion of the protein up to
and including the Tudor domain) and carboxy-terminal (C) (the 39
portion of the protein after, but not including, the Tudor domain)
SMN regions (Fig 2A).
Ten independent transgenic strains for each type of construct
(C, N and FL) were generated and examined for their effects on
lethality when SMN activity was reduced or eliminated using
either tubulinGAL4 or actinGAL4, two ubiquitous GAL4 drivers. It
was difficult to differentiate between the lethal phases of many
strains in the tubulinGAL4 background, presumably due to its
higher levels of expression. Instead, we were able to use the timing
of lethality in the presence of actinGAL4 to choose three lines
([UAS-Smn-RNAi]
N4 (N4), [UAS-Smn-RNAi]
C24 (C24) and [UAS-
Smn-RNAi]
FL26B (FL26B)) that define a set of alleles representing
the broadest range of detectable lethality for further analysis
(Figure 3A).
Of all strains generated, N4 displayed the most severe
phenotype, causing mortality at the early pupal stage. C24 was
less severe and results in lethality at a later pupal stage than N4,
while FL26B was semi-viable and was therefore the weakest allele
of the three (Figure 3A). Under the control of the tubulinGAL4
driver, N4 caused a similar phenotype to those observed for the
Smn
73Ao and Smn
f05960 mutations, suggesting that N4 is a strong
hypomorphic Smn allele (data not shown). The efficiency of RNAi
in the N4 and C24 strains precluded us from testing whether
ectopic SMN expression could rescue the RNAi-induced lethality.
A Drosophila Model of SMA
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induced by the expression of tubulinGAL4-directed FL26B is
completely rescued by the addition of the UAS-FLAG-Smn
construct to this genetic background (data not shown).
Consistent with these results, examination of protein derived
from 3
rd instar larvae from the above strains in the presence of the
actinGAL4 driver revealed significant reductions in SMN expres-
sion levels (Figure 3D), further suggesting the observed lethality is
the direct result of SMN protein attenuation. Though the three
strains did not display apparent differences in the degree of
reduction of SMN under these conditions, the genetic results with
respect to viability and subsequent experiments investigating NMJ
morphology (see below) strongly suggest these RNAi-induced Smn
strains result in varying degrees of SMN activity and therefore,
alleles of different strengths. Importantly, these reagents provide
important genetic tools that will allow us to examine the
requirement of SMN in muscle and neurons.
Loss of Smn causes neuromuscular junction defects
SMA patients experience motor neuron degeneration and
muscle atrophy [1,4]. Consistent with this, previous work has
shown that a loss of Smn function results in defects at the Drosophila
NMJ [15]. To confirm and extend these results, we examined the
NMJ phenotype observed in various Smn genetic backgrounds by
quantitatively assessing the morphology of the NMJ through
examination of synaptic bouton numbers between muscles 6 and 7
of the 3
rd instar larval NMJs. These boutons are visualized by
using antibodies against the Synaptotagmin (SYT) (pre-synaptic)
and DLG (post-synaptic) proteins, respectively (Figure 4A–G)
(Materials and Methods [29,31,32]). The following Smn genotypes,
Figure 1. SMN localizes to the post-synaptic region of the Drosophila NMJ. (A–D) SMN expression at the NMJ between muscle fibers 6 and 7.
(A) Pre-synaptic anti-HRP staining (red), (B) post-synaptic anti-DLG staining (blue), (C) anti-SMN staining (green) and (D) a merge of (A–C). SMN
expression co-localizes with DLG at the post-synaptic region of the NMJ. (E) SMN staining is also observed in muscle fibers and discrete foci in nuclei
(arrow). (F) Though no pre-synaptic SMN staining is observed, robust levels of SMN expression are seen in the larval brain. Scale bars in (D), (E), (F)
represent 10 mm, 20 mm, and 50 mm.
doi:10.1371/journal.pone.0003209.g001
A Drosophila Model of SMA
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rd instar larval stages
(Smn
73Ao/Smn
f01109, Smn
f05960/Smn
f01109 and Smn
f01109/Smn
f01109)
and therefore amenable to dissection, were examined.
The most severe reduction in NMJ bouton numbers was observed
in a Smn
73Ao/Smn
f01109 genetic background (Figures 4A–D and F).
The semi-viable Smn
f01109 mutation displayed a moderate reduction
in NMJ bouton numbers, consistent with its weakly hypomorphic
nature (Figure 4C). Surprisingly, the strong loss of function Smn
f05960
mutation, though homozygous lethal, failed to exhibit a detectable
change in NMJ bouton numbers in an Smn
73Ao background.
However, an increase in pre-synaptic ghost bouton numbers
[33,34] (where pre-synaptic SYT was not accompanied with post-
synaptic DLG) was observed in these individuals (Figure S3),
indicating that the Smn
f05960 allele does, indeed, disrupt NMJ
Figure 2. Smn mutations cause lethality. (A) Schematic representation of the SMN protein and location of mutations corresponding to the Smn
alleles used in this study. The conserved Tudor domain and YG box are indicated. Insertion sites of the transposon induced Smn
f05960 and Smn
f01109
alleles are denoted by triangles. Regions of the Smn transcript targeted by RNA interference (RNAi) are illustrated as lines under the SMN protein
schematic. (B) Loss of Smn function elicits lethality. For individuals of given phenotypes, the percentages of surviving individuals are shown and are
normalized to wild-type. Smn
73Ao and Smn
f05960 homozygotes die during late 2
nd/early 3
rd larval and pupal stages, though some Smn
f05960 escapers
are detected. In contrast, 67% of the Smn
f01109 homozygotes survive to adulthood. Smn
f01109/Smn
73Ao and Smn
f05960/Smn
73Ao trans-heterozygous
combinations are also viable. In addition, a small deficiency uncovering the entire Smn transcript was generated (Df(3L)Smn
X7). We crossed all three
Smn alleles to Df(3L)Smn
X7 and found that both Smn
73Ao/Df(3L)Smn
X7 and Smn
f05960/Df(3L)Smn
X7 heterozygotes die between the 2
nd and 3
rd instar
larval stages, while ,60% of Smn
f01109/Df(3L)Smn
X7 are viable. Therefore, using lethality as a criterion, all three alleles behave as loss-of-function
mutations with Smn
f01109 displaying the weakest phenotype of the three. No obvious maternal or paternal effect is observed for the different alleles.
m: maternal contribution, p: paternal contribution. WT is wild-type (Canton-S). At least 100 individuals were examined for each genotype.
doi:10.1371/journal.pone.0003209.g002
A Drosophila Model of SMA
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73Ao/Smn
f01109
individuals was rescued partially by neuronal or muscle-directed
expression of a UAS-FLAG-Smn transgene (Figure 4E–G), suggesting
that SMN expression in either tissue is sufficient to restore, at least
partially, NMJ morphology.
Loss of Smn function in muscles causes lethality
Though it is clear that global reduction of SMN function elicits
a larval lethal phenotype (Figure 2B), the relative requirement of
SMN in muscle versus neuron remains unresolved. We sought to
address this question directly through use of our inducible Smn
RNAi strains (N4, C24 and FL26B), which can be expressed using
tissue-specific GAL4 drivers. Therefore, we chose to reduce SMN
expression in neuronal and muscle lineages using the pan-neuronal
elavGAL4 [35] and pan-muscle how24BGAL4 drivers, respectively
(how24BGAL4 is a mesodermal driver that expresses in all muscles,
and in the remainder of the text we refer to it as a muscle driver)
[36,37].
Figure 3. Lethality strongly associates with loss of Smn function in muscle. Survival rates of animals expressing the N4, C24 and FL26B
transgenic UAS-Smn-RNAi constructs under the control of the actinGAL4 (A), how24BGAL4 (B), and elavGAL4 (C) drivers were measured at the
following developmental stages: embryo (day 0), 1
st instar larva (day 2), 3
rd instar larva (day 5), early pupa (day 7), late pupa (day 9), 2-day old adult
(day 12). Each experiment was performed in triplicate. The empty pWIZ RNAi vector served as a control. The survival rates of animals were calculated
and subtracted from control values. The N4, C24 and FL26B transgenic animals displayed graded viability among the drivers tested. Ubiquitous SMN
knockdown (A) leads to pupal lethality. Muscle-specific SMN knockdown (B) leads to late pupal lethality only in animals harboring the stronger alleles
(N4 and C24), whereas greater than 90% of FL26B individuals survive to adulthood. In contrast, reduction of SMN in neurons using N4 and C24 (C)
causes only very mild lethality (7%) when compared to control animals. (D) Western blots using an anti-SMN polyclonal antibody show reduction of
SMN protein in 3
rd instar larvae for all three UAS-Smn-RNAi transgenic strains in combination with the ubiquitous actinGAL4 driver. The top panel
shows a graded effect on SMN protein levels by the three constructs consistent with their effects on lethality. The bottom panel shows anti-a tubulin
levels, which served as loading controls.
doi:10.1371/journal.pone.0003209.g003
A Drosophila Model of SMA
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numbers, between muscles 6 and 7 in the A2 segment was observed in different genetic backgrounds using the pre-synaptic (Synaptotagmin) and
post-synaptic (Discs large) markers, shown in green and red, respectively. The following genotypes were examined: (A) wild-type (Canton-S), (B)
Smn
f05960/Smn
f01109 (C) Smn
f01109/Smn
f01109, (D) Smn
73Ao/Smn
f01109. Of these combinations, Smn
73Ao/Smn
f01109 displayed the most robust NMJ defect.
These defects are partially rescued by either (E) neuron-specific expression (elavGAL4) or (F) muscle-specific expression (how24BGAL4)o faUAS-FLAG-
Smn transgene. (G) More complete rescue was achieved when this transgene was expressed using both drivers simultaneously. Bouton numbers
were normalized to the ratio of the muscle area. Scale bars represent 20 mm. (H) Diagram of bouton numbers for genotypes from (A–F), normalized
for muscle area. * P,0.05 was determined by the ANOVA multiple comparisons test. For each genotype at least 15 animals were examined.
doi:10.1371/journal.pone.0003209.g004
A Drosophila Model of SMA
PLoS ONE | www.plosone.org 6 September 2008 | Volume 3 | Issue 9 | e3209Reduction of SMN in either tissue causes lethality, however, loss
of SMN expression in the muscle results in an earlier onset of
lethality, which we consider to be a more severe phenotype
(Figure 3B–C).InthestrongestSmnRNAiallele,N4,muscle-specific
SMNreductionresults in70% mortality(Figure 3B),while neuronal
specific reduction results in 7% mortality (Figure 3C). As RNAi is
less efficient in neurons, we added a GAL4-driven dicer construct to
increase the efficacy of SMN reduction under these conditions [38];
this resulted in no obvious enhancement of lethality in all Smn RNAi
and elavGAL4 backgrounds (data not shown). The GAL4 repressor
GAL80 was expressed in neurons using the pan neuronal n-syb
driver [39] to overcome the potential leakiness of the how24BGAL4
driver. Since the lethality observed for muscle specific reduction of
SMN more closely resembles ubiquitous SMN reduction (compare
Figure 3A and B), these indicate the requirement of SMN in the
muscle (using how24BGAL4) is more important for viability than its
requirement in the neurons.
Muscle and neuronal expression is required for normal
NMJ morphology
Similar to the tissue-dependent lethality experiments above, we
sought to assess the impact SMN activity has on NMJ morphology
using our UAS-Smn-RNAi strains, which can be expressed using
tissue-specific GAL4 drivers.
We selectively reduced SMN expression in neuron and muscle
tissues by crossing the UAS-Smn-RNAi alleles to the elavGAL4 and
how24BGAL4 drivers as they provide the earliest tissue specific
expression and most robust lethal effect (Figure 3 and data not
shown). Visualized by SYT (pre-synaptic) and DLG (post-synaptic)
staining, NMJs of Smn RNAi animals containing either a muscle-
or neuron-specific GAL4 driver revealed a reduction in the
number of synaptic boutons compared to vector alone controls
(Figure 5A–M). In the N4 strain, both neuron and muscle specific
attenuation of SMN cause approximately 50% reduction in
bouton numbers (Figure 5B, C, K–M), a reduction comparable to
what is observed in Smn
73Ao/Smn
f01109 larvae (Figure 4D, H).
Therefore, we conclude that the NMJ morphology is dependent
upon both pre- and post-synaptic SMN activity.
Previous studies demonstrated that mutations in Smn cause a
decrease in staining for the post-synaptic neurotransmitter receptor
subunit, GluRIIA [15]. To corroborate these results and to extend
our characterization of the tissue-specific requirement of SMN at
the NMJ, we examined the GluRIIA [40,41,42] expression pattern
(See Materials and Methods) in the UAS-Smn-RNAi backgrounds.
We found a consistent and significant quantitative reduction in
synaptic GluRIIA levels when Smn expression was decreased using
either neuron- (elavGAL4) or muscle-specific (mhcGAL4) drivers.
GAL4-only controls had no significant effect on GluRIIA staining
intensity. Consistent with the trend observed for the severity of the
lethal phenotype, the strongest Smn RNAi alleles caused the greatest
reduction in GluRIIA expression levels, suggesting that GluRIIA
levels are sensitive to the dose of functional SMN protein and thus,
would be a useful phenotypic metric in which to validate potential
modifiers of the Smn NMJ phenotype.
Our analysis indicates that normal NMJ morphology requires
SMN activity in both muscle and neurons. However, it appears
that loss of SMN activity in the muscle causes a more severe lethal
phenotype (Figure 3B), a conclusion that is consistent with the
finding that the SMN protein is concentrated in the post-synaptic
regions in muscle (Figure 1A–D).
Identification of genetic modifiers of Smn
To gain insights into the genetic circuitry capable of modulating
SMN activity in vivo, we employed a genetic approach to screen for
genes that affect Smn-dependent processes using the Exelixis
collection of transposon-induced mutations [25,26]. The benefits
of using the collection in a genetic screen have been previously
described [24]. Notably, the collection covers approximately 50%
of the genome and harbors both gain- as well as loss-of-function
mutations when exposed to GAL4 due to the presence of UAS
sequences within the insertional transposons [25,26]. While the
molecular coordinates of each insertion site is known, gene
assignments are sometimes ambiguous, as the modifying transpo-
son may have inserted between two genes.
The screen was carried out in two stages to identify both
enhancers and suppressors of Smn-associated lethality (Figure 6).
The strong correlation observed between the degree of lethality
and NMJ phenotypes using the Smn RNAi lines suggested the use
of lethality as a screening parameter would be successful in
identifying components of the SMN genetic network that might
also affect the NMJ. Both phases of the screen utilized the Smn
73Ao
allele, which gives a robust NMJ defect, and importantly, contains
a point mutation in the YG box (Figure 2A), which is the location
of a documented human SMN1 mutation [3].
The first stage was an F1 screen designed to identify insertions
that produced synthetic lethality or semi-lethality (Materials and
Methods) in an Smn heterozygous background, which will
hereafter be referred to as enhancers. Using this criterion, we
screened the entire Exelixis collection and identified 17 insertions
that result in Smn
73Ao/+ lethality (Figure 7).
In the second stage of the screen we tested for the ability of
mutations to suppress Smn-dependent larval lethality. This was
accomplished using offspring from the F1 screen that failed to
generate synthetic lethality. In this phase, we screened 7170 strains
(as Smn
73Ao is located on the third chromosome, we excluded third
chromosome insertions) and identified ten suppressors of homo-
zygous Smn
73Ao lethality (Figure 7).
NMJ analysis of Smn modifiers
To correlate modifier activity with the NMJ, we investigated
whether all of the Smn modifiers (10 suppressors and 17 enhancers)
could disrupt Smn RNAi-dependent NMJ defects, using synaptic
GluRIIA staining as an assay to quantify the degree to which the
Smn phenotype was modified by the interacting mutation. For this
assay, we employed the C24 Smn RNAi line because it displays
intermediate phenotypic strength. In all but two cases, the
combination of the modifier insertion mutation induced a
statistically significant change in the C24 GluRIIA phenotype
(Figure 7 and Figure S5 and S6). Amongst the validated modifier
insertions, the degree of enhancement or suppression varied
depending on the locus; control crosses demonstrated that there
were no significant Smn-independent changes in GluRIIA localiza-
tion for the tested insertion lines. Three lines (f04448, d09801 &
d00698) failed to modify C24 GluRIIA staining and were retested
using a weaker Smn RNAi strain, N13 (Strain f04448 and d09801
enhanced, whereas d00698 showed no interaction (data not shown),
highlighting the importance of the NMJ phenotype as a secondary
screening tool (Figure 7)). Thus, the majority modifiers of the
Smn
73Ao lethal phenotype were confirmed by a second, independent
assay. All but one of these insertions modified the Smn NMJ
phenotype, validating the efficacy of the screen and suggesting that
the screen may prove to be an effective tool in the identification of
candidate genes that may be relevant to the SMA disease state.
Neuronal overexpression of wishful thinking (wit)
enhances Smn NMJ defects
To validate further our approach, we sought to examine the
relationship between wishful thinking (wit) and Smn in greater detail.
A Drosophila Model of SMA
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implicated in NMJ function [27,28] and thus could serve as a
paradigm for validating the ability of the screen to identify bona fide
Smn genetic modifiers.
wit encodes a type II BMP receptor that functions as a
retrograde signaling component in neurons [27,28]. wit loss-of-
function mutations cause NMJ defects, whereas wit gain-of-
function causes no obvious NMJ morphological changes. As the
wit allele identified as an Smn enhancer, wit
d02492, is associated with
a GAL4-responsive transposon, it seemed likely that it represented
a gain-of-function mutation. Consistent with this notion, an
independent UAS-wit transgene [27,28] behaved in a similar
Figure 5. Muscle and neuron specific Smn RNAi knockdown causes NMJ defects. (A–I) Reduced SMN expression in the N4, C24 and FL26B
UAS-Smn-RNAi transgenic constructs elicits graded effects on NMJ morphology using the ubiquitous actinGAL4 (A, D, G) as well as the tissue-specific
how24BGAL4 (muscle) (B, E, H) and elavGAL4 (neuron) (C, F, I) drivers. Vector only (pWIZ) controls are shown (J, K, L). In these images the pre- and post-
synaptic tissues are labeled with antibodies against Synaptotagmin (green) and Discs large (red), respectively. (M) Bouton counts for the NMJs from
the genotypes shown in (A–L) were normalized for muscle area and subtracted from vector only controls. For each genotype at least 15 animals were
examined. * P,0.01 and **P,0.05 was determined by the ANOVA multiple comparisons test. Scale bars represent 15 mm.
doi:10.1371/journal.pone.0003209.g005
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d02492 under the conditions used in our screen (data
not shown). In addition, we detected increased expression of WIT
in wit
d02492 animals containing tissue-specific GAL4 drivers (data
not shown).
Over-expression of WIT in neurons using the neuron-specific
elavGAL4 driver in either an Smn
73Ao or an Smn
f01109 heterozygous
background resulted in reduced NMJ bouton numbers relative to
elavGAL4 Smn
73Ao/+, elavGAL Smn
f01109/+ and UAS-wit; elavGAL4
controls (Figure 8). This result suggests that the Smn-dependent
NMJ phenotype is sensitive to elevated WIT levels.
A Mad mutation enhances the Smn NMJ phenotype
Given the involvement of wit at the NMJ and its interaction with
Smn, we hypothesized that an Smn heterozygous background leads
to an increase in sensitivity to the dosage of BMP during NMJ
development. Thus, under conditions of elevated levels of WIT in
Smn heterozygotes, it is possible that normal BMP signaling at the
NMJ is altered, perhaps due to titration of the BMP ligand,
thereby resulting in NMJ defects. If this hypothesis is correct,
mutations of the BMP components downstream of wit should also
enhance the Smn NMJ phenotype. Therefore, we tested whether
Mothers against dpp (Mad) and Smn interaction at the NMJ. Mad
encodes the Drosophila homolog of R-Smad, a downstream effector
of the pathway [34,43,44]. Pathway activation leads to phosphor-
ylation of MAD (pMAD), and its subsequent translocation to the
nucleus where it regulates gene expression [34,43,44]. To examine
the consequences of Smn/Mad interaction at the NMJ, we used the
hypomorphic Mad
12 allele [34] in combination with multiple Smn
alleles to monitor the phenotypic effects at the NMJ. The
moderate reduction in number of NMJ boutons caused by the
hypomorphic Mad
12 allele (Figure 9D and G) is clearly
exacerbated by mutations in Smn (Figure 9E–G). These results
suggest that perturbations in BMP signaling are able to modify
Smn-dependent phenotypes at the larval NMJ.
SMN activity affects BMP signaling
To further validate the link between SMN and the BMP
signaling pathway we examined the effect of reduced SMN levels
on pMAD expression. Though Mad is required for retrograde
signaling in neurons at the NMJ [34,45], a lack of detectable
pMAD staining at the NMJ precluded the use of the NMJ as a
means to assess whether SMN can affect its expression. Instead, we
examined the pMAD expression pattern adjacent to the anterior-
posterior compartment boundary of 3
rd instar larval wing discs
[46] (Figure 10) using engrailedGAL4 and vestigalGAL4 directed
expression of the N4 RNAi transgene (Figure 10 and Figure S4
respectively). Regions in which SMN levels are reduced display
attenuated pMAD staining (Figure 10C–E). Moreover, adult wing
abnormalities occur in regions of reduced SMN expression,
including thicker wing veins and shorter posterior cross-veins
(Figure 10F). These phenotypes are similar to phenotypes elicited
by mutations in other BMP pathway components such as thickveins
(tkv) and glass bottom boat (gbb) [45,47,48]. Thus, BMP signaling in
the wing appears to be affected by loss of SMN activity through
the regulation of activated Mad, corroborating the link between
Smn and the BMP signaling pathway.
A Dad loss of function allele is capable of rescuing Smn
NMJ defects
We extended these observations by probing the relationship
between the BMP pathway antagonist, Daughters against dpp (Dad),
and Smn. Dad encodes the Drosophila homolog of mammalian anti-
Smad and acts as a Mad antagonist [44,49,50]. Since Dad mutants
exhibit pre-synaptic overgrowth [49], we tested whether the
Dad
271-68 null mutation could rescue the Smn NMJ phenotype.
Consistent with previous reports [49], 3
rd instar larvae homozy-
gous for Dad
271-68 display more dispersed SYT expression at the
NMJ than control larvae (Figure 11C). However, in contrast to
previous studies, we found the total bouton number, as determined
by DLG post-synaptic staining, was only slightly reduced.
Importantly, the Smn
73Ao/Smn
f01109 NMJ phenotype was sup-
pressed by the introduction of Dad
271-68 (Figure 11B, D, E),
providing genetic evidence that a third element of the BMP
pathway interacts with Smn. It appears that elevating BMP activity
through a complete loss of Dad function suppresses the effects of
Smn mutations on the NMJ (Figure 11D, E). A prediction of this
model is that pharmacological reagents that increase BMP
signaling may ameliorate Smn-associated NMJ defects, thereby
identifying a set of targets of potential therapeutic value.
Discussion
SMN1 is the determining gene for Spinal Muscular Atrophy
(SMA) [5], a devastating neurodegenerative disease in humans
with no currently available FDA-approved drug treatment.
Though the general biochemical function of SMN in snRNP
assembly has been well documented [51,52,53], much remains to
be learned about its action at the NMJ and the genetic circuitry
that is capable of affecting SMN activity. Specifically, it remains
unclear whether the NMJ pathology in SMA is due to the
ubiquitous loss of SMN function or whether SMN has a unique
role at the NMJ. Here, we have utilized Drosophila to investigate the
tissue specificity of Smn and to identify genes that interact with Smn.
Figure 6. Schematic representation of the Smn modifier screen.
Depicted are the crosses performed to identify enhancers and
suppressors of Smn-associated lethality. In the first stage of the screen,
designed to identify Smn enhancers, Smn
73Ao tubulinGAL4 e/TM6B virgin
females were mated to males from Exelixis collection strains. In this
stage, the entire Exelixis collection, which affects approximately 50% of
the Drosophila genome, was tested. In the F1 generation, mutations
that resulted in synthetic lethality or reduced viability in trans with the
Smn
73Ao tubulinGAL4 e chromosome were defined as enhancers. In the
second stage of the screen, males from F1 crosses that failed to show
enhancement (P[Exelixis]/+; Smn
73Ao tubulinGAL4 e/TM6B) were mated
to Smn
73Ao e/TM1, Me ´ virgin females to identify mutations that
suppressed the Smn
73Ao tubulinGAL4 e/Smn
73Ao, e lethal phenotype.
We performed the F2 suppressor screen with Exelixis mutations on first
and second chromosomes as testing third chromosome mutations
would require placing these mutations in cis with Smn. Additional
assays were employed to eliminate false positives (See Materials and
Methods). Seventeen enhancers and ten suppressors met these criteria.
All 27 modifiers were subsequently examined for their ability to modify
the Smn NMJ phenotype by GluRIIA staining (Figures S5 and S6).
doi:10.1371/journal.pone.0003209.g006
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PLoS ONE | www.plosone.org 9 September 2008 | Volume 3 | Issue 9 | e3209Figure 7. Modifiers of Smn phenotypes. Listed are the insertions that enhance (top) or suppress (bottom) Smn
73Ao-dependent lethality. Due to
the site of transposon insertion, unambiguous gene assignments were not possible in all instances (shaded). Strains whose designations begin with
‘‘d’’ or ‘‘f’’ contain GAL4 responsive elements (UAS), whereas strains beginning with ‘‘c’’ or ‘‘e’’ are not GAL4-inducible. Gene assignments were
determined using FlyBase (http://www.flybase.org/). Human homologs were determined using NCBI BLAST, NCBI UniGene (NCBI) (http://www.ncbi.
nlm.nih.gov/sites/entrez?db=unigene) or ENSEMBL genome browser (http://www.ensembl.org). Annotated functions were determined based on
FlyBase, NCBI Entrez Gene and SMART (http://smart.embl-heidelberg.de/). Modification of the NMJ morphology between muscles 6 and 7 in the A2
segment was assayed in the elavGAL4 pWIZ[UAS-Smn-RNAi]
C24 background in trans with all identified modifiers using the pre-synaptic (Horseradish
peroxidase) and post-synaptic (GluRIIA) markers (see Materials and Methods). In the three cases that did not show significant phenotypic alteration,
additional pWIZ[UAS-Smn-RNAi]
N13 allele was also used (see text). The degrees of change observed in GluRIIA staining were categorized as follows:
+++, strong; ++, moderate; +, weak; N.E., No Effects.
doi:10.1371/journal.pone.0003209.g007
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PLoS ONE | www.plosone.org 10 September 2008 | Volume 3 | Issue 9 | e3209Figure 8. wit overexpression in neurons exacerbates Smn-dependent NMJ defects. A gain-of-function mutation of wishful thinking (wit),
wit
d02492, was identified as an enhancer in our screen. To further investigate the interaction between wit and Smn at the NMJ, we used the neuron-
specific driver, elavGAL4 to express WIT in neurons. (A–F) The morphology of the NMJ, as judged by bouton numbers, between muscles 6 and 7 in the
A2 segment was observed in different genetic backgrounds using the pre-synaptic (Synaptotagmin) and post-synaptic (Discs large) markers, shown
in green and red, respectively. The following genotypes were examined: (A) elavGAL4/+, (B) elavGAL4, Smn
73Ao/+, (C) elavGAL4, Smn
f01109/+, (D)
elavGAL4/UAS-wit2A, (E) elavGAL4, Smn
73Ao/UAS-wit2A, (F) elavGAL4, Smn
f01109/UAS-wit2A, (G) Bouton counts for genotypes from (A–F and wild-type).
Consistent with previous reports, neural induced expression of the UAS-wit2A transgene had no obvious effect on NMJ bouton number. A synergistic
effect was observed upon the addition of a single Smn allele (Smn
73Ao or Smn
f01109) to this background, leading to a reduction of NMJ bouton
numbers. The phenotype was more severe in the Smn
f01109 background. Smn
f01109 showed an approximate 50% reduction in bouton numbers while
Smn
73Ao reduced the bouton count by 20%. elavGAL4, Smn
73Ao/+ (B) and elavGAL4, Smn
f01109/+ (C) individuals display no significant reduction in NMJ
bouton numbers compared to wild-type (G). Bouton counts were determined as above. Error bars are s.e.m.; * P,0.02 was determined by the ANOVA
multiple comparisons test to wild-type and all controls. n was 15–20 animals for each genotype. Bouton numbers for each genotype were normalized
to the ratio of muscle areas. Scale bars represent 20 mm.
doi:10.1371/journal.pone.0003209.g008
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PLoS ONE | www.plosone.org 11 September 2008 | Volume 3 | Issue 9 | e3209Figure 9. Loss of mad function enhances Smn NMJ defects. (A–F) The morphology of the NMJ, as judged by bouton numbers, between
muscles 6 and 7 in the A2 segment was observed in different genetic backgrounds using the pre-synaptic (Synaptotagmin) and post-synaptic (Discs
large) markers, shown in green and red, respectively. The following genotypes were examined: (A) wild-type, (B) Smn
73Ao/+, (C) Smn
f01109/+, (D)
mad
12/+, (E) Smn
73Ao/mad
12 and (F) Smn
f01109/mad
12. (G) Bouton counts for genotypes in (A–F). Introduction of mad
12 into either a Smn
73Ao/+ or a
Smn
f01109/+ background dominantly reduces the Smn-dependent NMJ bouton count. Error bars are s.e.m.; *P,0.02 was determined by the ANOVA
multiple comparisons test to wild-type and all controls. n was 15–20 animals for each genotype. Bouton numbers for each genotype were normalized
to the ratio of muscle areas. Scale bars represent 20 mm.
doi:10.1371/journal.pone.0003209.g009
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into the role of SMN at the NMJ, may also define novel
therapeutic targets.
Previous studies based primarily on the analysis of the Smn
73Ao
allele demonstrated that reduced Smn activity causes lethality and
NMJ morphological defects [15]. We corroborated these obser-
vations through the examination of several extant and novel Smn
mutations of varied severities, including several GAL4-inducible
Smn RNAi alleles generated for this study. These hypomorphic
strains reduce SMN expression levels to different degrees in a
Figure 10. Smn knockdown reduces pMAD signals. (A–B) Wild-type wing discs from 3
rd instar larvae were stained with antibodies against SMN
(red) (A) and phosphorylated MAD (pMAD) (green) (B). (C–D) 3
rd instar wing discs of engrailedGAL4, pWIZ[UAS-Smn-RNAi]
N4 animals are stained with
antibodies against SMN (red) (C) and pMAD (green) (D). (E) Merge of (C) and (D). pMAD staining is reduced in the posterior region of the wing disc
where SMN expression is decreased (yellow line). (F) A wing from an engrailedGAL4, pWIZ[UAS-Smn-RNAi]
N4 transgenic adult exhibits defects in the
posterior crossvein regions and the distal portions of wing veins L4 and L5 (arrow). Scale bars represent 40 mm.
doi:10.1371/journal.pone.0003209.g010
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SMA patients. Additionally, these strains may model the dosage-
dependent nature of SMA [1,2] as the developmental arrest
associated with these animals correlates with the extent of
morphological abnormalities observed at the NMJ.
Our examination of Smn NMJ structure in Drosophila using pre-
and post-synaptic markers, SYT and DLG, respectively, revealed
significant losses of synaptic bouton numbers in multiple Smn
backgrounds (Figure 4). Moreover, in these backgrounds, we also
detected reduced post-synaptic GluRIIA expression (data not
Figure 11. A dad null allele rescues Smn NMJ defects. (A–D) The morphology of the NMJ, as judged by bouton numbers, between muscles 6
and 7 in the A2 segment was observed in different genetic backgrounds using the pre-synaptic (Synaptotagmin) and post-synaptic (Discs large)
markers, shown in green and red, respectively. The following genotypes were examined: (A) wild-type (B), Smn
73Ao/Smn
f01109, (C) dad
271-68
homozygotes and (D) Smn
73Ao dad
271-68/Smn
f01109 dad
271-68. (E) Bouton counts for genotypes in (A–D). Smn
73Ao/Smn
f01109 individuals display strongly
reduced NMJ bouton numbers while dad
271-68 homozygotes have a greater than two-fold of bouton numbers relative to the Smn
73Ao/Smn
f01109
animals. The Smn
73Ao dad
271-68/Smn
f01109 dad
271-68 double mutants behave like dad
271-68 homozygotes. Error bars are s.e.m.; n is 15–20 animals for
wild-type and Smn
73Ao/Smn
f01109. n is 30 for dad
271-68/dad
271-68 and Smn
73Ao, dad
271-68/Smn
f01109, dad
271-68.* P,0.002 by the ANOVA multiple
comparisons test. Bouton numbers for each genotype were normalized to the ratio of muscle area. Scale bars represent 15 mm.
doi:10.1371/journal.pone.0003209.g011
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73Ao NMJ [15].
Together, these results suggest that loss of SMN function in
Drosophila causes aberrant neuromuscular synaptic structure,
mimicking the pathology of SMA [1,54]. In addition, these
structural abnormalities are consistent with the altered electro-
physiological profile previously observed in Drosophila Smn
73Ao
animals [15]. It should be noted that other glutamate receptor
subunits display altered transcriptional profiles in a Smn
73Ao
background; specifically the GluRIIA and GluRIIB transcript
levels were decreased while GluRIIC levels were increased [55].
Therefore, combining genetic and morphological analyses of
pathological changes in synaptic structure with future electrophys-
iological studies will be necessary to understand more thoroughly
the synaptic consequences of SMN loss in SMA.
A longstanding question in the pathology of SMA is the relative
neuronal and muscle contribution of SMN function. The RNAi
strains allowed us to reduce SMN function in a tissue-specific
fashion and therefore, address this issue directly. We find that
SMN is required in both neurons and muscle for normal NMJ
morphology as GAL4-inducible RNAi reduction of SMN in
neurons and muscle both show a decrease in NMJ bouton
numbers (Figure 5) and GluRIIA staining (Figures S5 and S6 and
data not shown). In addition, expression of SMN in either tissue
is sufficient to partially rescue NMJ defects associated with loss
of Smn function (Figure 4E–G). These results are consistent
with previous reports in Drosophila, zebrafish and mouse
[15,16,54,56,57,58,59] that indicate an interdependence of
neuron and muscle SMN activity.
In contrast to a requirement for Smn in both muscle and neurons
at the NMJ, we demonstrated that muscle specific reduction of Smn
causes a more severe lethal phenotype (Figure 3B–C). We do not
know the cause of the lethality. It is possible that the earlier onset
of lethality observed for the how24BGAL4 reduction of SMN may
result from the leakiness of the driver or loss of SMN activity in
dividing cells (the elavGAL4 driver expresses predominantly in post-
mitotic cells). However, our results raise the possibility that the
organism is more vulnerable to SMN reduction in the muscle.
This is also consistent with the post-synaptic concentration of
SMN at the NMJ (Figure 1). The functional relevance of these
observations remains to be determined; however, a previous report
has suggested that Smn may have a specific function in the
Drosophila adult skeletal muscle where SMN is expressed in the
sarcomere and was shown to bind to a-actinin [18]. Together,
these data provide plausible explanations why muscle may be
rendered more susceptible to loss of Smn function.
Current therapeutic strategies for treatment of SMA are based
on the dosage dependent nature of the disease, focusing on drugs
that increase SMN2 transcription and splicing efficiency [60,61].
Though these strategies may ultimately prove successful in treating
SMA, complementary therapies may allow for the delivery of a
combination of drugs as this has been shown to be successful in
alleviating the symptoms of other diseases, such as AIDS [62].
Hence, the identification and, ultimately, the manipulation of
genetic elements that affect SMN activity may be necessary to
treat SMA effectively. Though previous biochemical studies
provide valuable and fundamental knowledge of SMN function,
our current understanding of SMN has been limited mainly to its
binding partners and a few genetic modulators [12,19]. Thus, we
performed a genome-wide genetic screen in Drosophila to identify
novel components of the Smn genetic circuitry to broaden our
knowledge of its function and to seek potentially novel therapeutic
approaches beyond the augmentation of SMN2 expression.
Since we observed that the severity/onset of Smn-dependent
mortality (Figure 3) corresponds to the degree of NMJ defects
(Figure 5), we reasoned the identification of enhancers and
suppressors of Smn
73Ao-dependent lethality would be likely to yield
genes that also function at the NMJ. Our genetic screen using an
allele (Smn
73Ao) that encodes a point mutation seen in SMA
patients [3] resulted in the identification of twenty-seven modifiers
of Smn lethality. Though we recognize the genetic circuitry in
Drosophila may differ from that which exists in humans, we expect
there to be substantial overlap given the conservation of gene
function across species.
Despite the essential role of SMN in snRNP assembly [12], an
unexpected result of the screen was that none of the modifying
insertions for which unambiguous gene assignments were made
appear to function in RNA processing. Consistent with this notion,
direct attempts to identify genetic relationships between SMN and
known components of the SMN multimeric complex, including
deficiencies that uncover the Drosophila Gemin homologs, did not
affect the Smn
73Ao heterozygous phenotype (data not shown). One
possible explanation is that removal of additional components of
the SMN complex may not enhance Smn-related phenotypes since
SMN activity is critical for the initial steps in SMN complex
assembly. Hence, altering the activity of ‘‘downstream’’ or directly-
interacting partners of the SMN in the SMN complex may not
affect Smn-related phenotypes.
Though none of the unambiguously identified modifier genes
have an obvious role in snRNP assembly; we did recover genes
(wishful thinking, fmr1 and cutup) that have been shown previously to
function at the NMJ [27,28,63,64]. Moreover, the majority of the
remaining genes, which had no previously known NMJ function,
also modified Smn NMJ phenotypes. Thus our genetic approach
was efficient in identifying genes related to Smn NMJ function.
This suggests that a similar approach utilizing a hypomorphic Smn
allele (e.g. UAS-Smn-RNAi) that more closely approximates the
dosage dependent nature of the human disease condition may
identify additional members of the Smn genetic circuitry.
An analysis of the interacting loci according to molecular
functions reveals an assortment of functional categories including
cytoskeleton interaction proteins (moe and ctp), transcription factors
(net) and metabolic enzymes (CG17323 and CG10561). Identified
interactors also include members of several signal transduction
pathways (e.g. BMP (wit), FGF (btl) and Nuclear Hormone
Receptor (Eip75B)), raising the possibility that these evolutionarily
conserved signaling pathways integrate with SMN or targets of
SMN function(s). Though more detailed analyses of the nature of
the links (synergistic or parallel) between these pathways and SMN
are necessary, we provide strong evidence supporting a connection
between BMP signaling and Smn at NMJ by testing additional
upstream and downstream elements of this pathway. Our
molecular genetic analysis clearly indicates that SMN influences
BMP activity. It remains to be determined whether SMN acts in
the muscle to influence retrograde BMP signaling through the
WIT receptor, for example by regulating the activity of the WIT
ligand (GBB). It is also possible that SMN functions cell-
autonomously in the neurons to affect the activity of MAD or its
antagonist, DAD. As the BMP signaling pathway has been
implicated in other neurodegenerative diseases, including Du-
chenne Dystrophy and Marfan Syndrome [65], it is probable that
BMP signaling also plays a role in the pathology of SMA in
humans.
Similar to what is observed in SMA, our results confirm the
susceptibility of the Drosophila NMJ to lower levels of SMN, and
our screen has also identified several genes that modify Smn NMJ
phenotypes. In other recent studies, micro-array based approaches
analyzed the effect of reduced Smn levels on tissue-specific gene
expression at a genome-wide level [52,55]. They identified genes
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genes involved in general metabolic processes [55]. These screens
are clearly a valuable means to assess the housekeeping function of
Smn. However, unlike the genes recovered from our screen, most
of which affect NMJ structure, it remains to be determined
whether the genes identified through transcriptional profiling are
involved in the development and/or maintenance of the NMJ.
Thus, our genetic approach has uncovered elements, revealing a
potential NMJ-specific role for Smn.
In this study, we have used Drosophila genetics to broaden our
understanding of Smn at the neuromuscular junction and probe the
genetic circuitry of Smn, illustrating the utility of a genetic
approach in the identification of novel genes that impact Smn
activity. Given the high degree of genomic conservation, use of
model systems such as Drosophila will, in our view, lead to a more
thorough understanding of SMA pathology and point to potential
therapeutic strategies.
Materials and Methods
Drosophila stocks
All stocks were maintained on standard cornmeal/yeast/
molasses/agar medium at 25uC. The Smn
73Ao, P{EP-
gy2}EY14384, wit
A12 and wit
B11 alleles were obtained from the
Bloomington Drosophila Stock Center (Bloomington, IN). The
Smn
f05960 and Smn
f01109 alleles are from the Exelixis collection at
Harvard Medical School. Dad
271-68 and Mad
12 were gifts from
Graeme Davis. P[UAS-wit2A] transgenic animals were gifts from
Hermann Aberle. To generate the P[UAS–FLAG-Smn] strains, a
full-length Smn cDNA was cloned into the amino-terminal FLAG-
tagged vector, FLAG-pUAST and introduced into w
1118 animals.
Several independent strains were isolated and subsequently tested
for their ability to rescue Smn-dependent lethality in a homozygous
Smn
73Ao e background. The majority of homozygous Smn
73Ao e
mutants die between 2
nd and 3
rd larval stages, and less than 10%
reach the 3
rd instar larval stage. Expression of this construct using
the ubiquitous actinGAL4 and tubulinGAL4 drivers partially
suppressed this lethality, as 50% of the animals survived to the
late pupal stage and 20% survived to the adult stage. The null
allele of Smn, Df(3L)Smn
X7, was generated by imprecise excision of
the P{EPgy2}EY14384. 1,626 excision events were isolated and
17 failed to complement Smn
73Ao, including Df(3L)Smn
X7.
Subsequent sequence analysis of Df(3L)Smn
X7 determined the
excision event removed almost the entire SMN transcript without
affecting nearby loci (93 bp upstream of the transcription start site
through all but the final 44 bp of the 39 UTR). To generate the
Smn RNAi constructs, three different portions of the Smn cDNA
were cloned into the pWIZ vector: the entire cDNA (FL
constructs), the amino-terminal portion up to and including the
entire Tudor domain (N constructs) and the carboxy-terminal
portion after, but not including, the Tudor domain (C constructs)
(Figure 2A). These constructs were then introduced into w
1118
embryos by germ-line transformation according to standard
procedures (by the CBRC fly core facility, Massachusetts General
Hospital). Multiple independent insertions were obtained for each
construct, including the pWIZ[UAS-Smn-RNAi]
N4, pWIZ[UAS-
Smn-RNAi]
C24 and pWIZ[UAS-Smn-RNAi]
FL26B transgenic strains
that were used for the analyses conducted in this study. Detailed
primer sets and methods used for sequencing Smn
f05960 and
Smn
f01109 alleles are available upon request.
Exelixis screen
The screen we performed combined elements from standard F1
and F2 screens. This ‘‘combination screen’’ was identical to a
standard F2 screen with the exception that the crosses were
designed to identify synthetic lethal interactions with Smn in the
F1. In this screen we utilized the Smn
73Ao allele in cis with a
ubiquitously expressed tubulinGAL4 driver (Lee and Luo, 1999).
Initially, Smn
73Ao tubulinGAL4 e/TM6B virgin females were crossed
to the entire Exelixis mutant collection to identify insertions that
elicit F1 synthetic lethality or reduced viability. From these results,
we arbitrarily defined a strain to be a candidate enhancer as one
that displayed a viability of less than 30%. In the second
generation, F1 males from strains that failed to elicit synthetic
lethality were crossed to Smn
73Ao e/TM1, Me ´ virgins to test for
their ability to suppress homozygous Smn
73Ao larval lethality. In the
F2 screen, candidate suppressors were identified by the presence of
individuals bearing the marker ebony (e), which is visible in both
pupae and adults.
Secondary genetic assays
We used several secondary genetic assays to evaluate candidate
modifiers. Initially, all candidate enhancers were crossed to
tubulinGAL4 e alone, to determine whether the observed effects
on viability were Smn-dependent.
Resultant strains and all candidate suppressors were then
crossed to stocks containing additional combinations of Smn alleles
and GAL4 drivers to observe their effects on viability. These stocks
included both Smn
f05960 and Smn
73Ao alone and in combination
with the tubulinGAL4 or actinGAL4 drivers. The actinGAL4 driver
alone was also tested. Twenty-seven strains modified Smn-
dependent lethality. Of these, seventeen were classified as
enhancers and ten as suppressors.
NMJ analysis of 27 Smn interactors
Strains containing all twenty-seven interactors in combination
with the pWIZ[UAS-Smn-RNAi]
C24 were generated. These were
tested for their ability to modify NMJ phenotype associated with
elavGAL4 (neuronal) directed expression of pWIZ[UAS-Smn-
RNAi]
C24 and pWIZ[UAS-Smn-RNAi]
N13. GluRIIA morphometric
analyses were performed as described previously [66].
Lethality assays
Fertilized eggs were collected on apple juice agar plates. Before
collection, adults were allowed to lay for 2 hours. All the F0 strains
were balanced by TM6B, Dfd:YFP, Tb or CyO Dfd:YFP, and the
non-YFP embryos were collected using a fluorescence dissection
scope (Zeiss). Fertilized embryos were then place onto fresh apple
juice plates containing yeast paste. Each plate contained 20–25
embryos to avoid over-crowding. The animals were allowed to
grow into different developmental stages in controlled temperature
(25 uC) and their survival was determined by visual inspection.
Immunohistochemistry and microscopy
Primary antibodies were used at the following dilutions:
monoclonal anti-DLG (1:500) (Developmental Studies Hybridoma
Bank), polyclonal anti-Synaptotagmin (1:1000) (a gift from Hugo
Bellen), polyclonal anti-SMN (1:250, NMJ staining), monoclonal
anti-SMN (1:500, wing disc), polyclonal anti-pMAD (1:250) (a gift
from Carl-Henrik Heldin). Anti-SMN monoclonal and polyclonal
antibodies were generated by immunizing animals with purified
full-length SMN protein with a 66His-tag fused to its carboxy-
terminus (Cocalico Biologicals, Inc.). Texas-red conjugated anti-
HRP (1:250), FITC- (1:40) and Cy5- (1:40) conjugated anti-rabbit
and anti-mouse secondary antibodies were purchased from
Jackson Immunoresearch Laboratories. For the NMJ analyses,
3
rd instar larvae were dissected and fixed for 5 minutes in Bouin’s
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rd instar
larvae in phosphate-buffered saline (PBS). Discs were kept on ice
until fixation in 3% paraformaldehyde in PBS. Stained specimens
were mounted in FluoroGuard Antifade Reagent (Bio-Rad), and
images were obtained with a Zeiss LSM510 confocal microscope.
Bouton numbers were counted based on the Discs large and
Synaptotagmin staining in the A2 segment between muscles 6 and
7. The ratio of muscle area for the various genotypes was
normalized to wild-type. GluRIIA morphometric analyses were
performed as described previously [66].
Supporting Information
Figure S1 Specificity of the anti-SMN antibodies. (A–C)
Wing discs from 3
rd instar larvae overexpressing the UAS-FLAG-
Smn transgenic rescue construct using the vestigalGAL driver were
stained with antibodies against the FLAG peptide (green) (A) and
SMN (red) (B). (C) Merge of (A) and (B) showing the overlapping
expression of SMN and FLAG within the vestigal expression
domain. (D) Wild-type and (E) vestigalGAL4, pWIZ[UAS-Smn-
RNAi]
N4 3
rd instar wing discs were stained with antibodies against
SMN (green). (F) Western blots of a serial dilution of S2 cell
extracts (1: 20 mg, 2: 40 mg, 3: 60 mg, 4: 80 mg total protein) using
the polyclonal (left) and monoclonal (right) antiserum against SMN
recognize a single band of approximately 28 kD in size.
Found at: doi:10.1371/journal.pone.0003209.s001 (4.46 MB TIF)
Figure S2 SMN post-synaptic staining is abolished by
muscle specific SMN knockdown. (A–F) The morphology of
the NMJ between muscles 6 and 7 in the A2 segment was observed
in different genetic backgrounds using antibodies against SMN
(green) and the post-synaptic marker, Discs large (red). (A–C)
Wild-type: anti-DLG (A), anti-SMN (B) and (C) merge of (A) and
(B). (D–F) Transgenic animals containing how24BGAL4 and
pWIZ[UAS-Smn-RNAi]
N4: anti-DLG (D), anti-SMN (E) and (F)
merge of (D) and (E). In this background, SMN staining is reduced
(E).
Found at: doi:10.1371/journal.pone.0003209.s002 (2.42 MB TIF)
Figure S3 Pre-synaptic ghost bouton counts are elevat-
ed in Smn animals. The morphology of the NMJ between
muscles 6 and 7 in the A2 segment was observed in different Smn
backgrounds using the pre-synaptic (Synaptotagmin) and post-
synaptic (Discs large) markers. Ghost bouton counts were
determined by assessing the numbers of boutons that stained
positive for Synaptotagmin and failed to stain for Discs large. All
combinations examined (Smn
73Ao/Smn
f01109, Smn
f05960/Smn
f01109
and Smn
f01109/Smn
f01109) displayed elevated numbers of pre-
synaptic ghost boutons when compared to wild-type.
Found at: doi:10.1371/journal.pone.0003209.s003 (0.21 MB TIF)
Figure S4 pMAD staining of vestigalGAL4, UAS-Smn-
RNAi transgenic animals. (A–B) 3
rd instar wing discs of
vestigalGAL4, pWIZ[UAS-Smn-RNAi]
N4 animals are stained with
antibodies against SMN (red) (A) and pMAD (green) (B). pMAD
staining is reduced in the dorsoventral boundary of the wing disc
where SMN expression is decreased (see Figure 10 for wild-type
control).
Found at: doi:10.1371/journal.pone.0003209.s004 (1.37 MB TIF)
Figure S5 NMJ analysis of Smn enhancers. Modification
of the NMJ morphology between muscles 6 and 7 in the A2
segment was assayed in the elavGAL4 pWIZ[UAS-Smn-RNAi]
C24
background in trans with all identified modifiers using the pre-
synaptic (Horseradish peroxidase (HRP)) and post-synaptic
(GluRIIA) markers (see Materials and Methods). In the three
cases (f04448, d09801 and d00698) that did not show significant
phenotypic alteration, the pWIZ[UAS-Smn-RNAi]
N13 allele was
also used. In this background, strain f04448 and d09801
enhanced, whereas d00698 showed no interaction (data not
shown and Figure 7).
Found at: doi:10.1371/journal.pone.0003209.s005 (0.74 MB TIF)
Figure S6 NMJ analysis of Smn suppressors. Modification
of the NMJ morphology between muscles 6 and 7 in the A2
segment was assayed in the elavGAL4 pWIZ[UAS-Smn-RNAi]
C24
background in trans with all identified modifiers using the pre-
synaptic (Horseradish peroxidase (HRP)) and post-synaptic
(GluRIIA) markers (see Materials and Methods).
Found at: doi:10.1371/journal.pone.0003209.s006 (0.78 MB TIF)
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